prenetics global ltd - PRE

PRE

Close Chg Chg %
17.94 -0.11 -0.61%

Closed Market

17.83

-0.11 (0.61%)

Volume: 222.45K

Last Updated:

Apr 17, 2026, 4:00 PM EDT

Company Overview: prenetics global ltd - PRE

PRE Key Data

Open

$17.99

Day Range

17.74 - 18.50

52 Week Range

4.15 - 23.63

Market Cap

$301.90M

Shares Outstanding

16.83M

Public Float

12.05M

Beta

0.27

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$4.11

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

153.48K

 

PRE Performance

1 Week
 
0.56%
 
1 Month
 
-9.12%
 
3 Months
 
13.46%
 
1 Year
 
344.64%
 
5 Years
 
N/A
 

PRE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About prenetics global ltd - PRE

Prenetics Global Ltd. is a health sciences company, which engages in providing consumer health products and services. The firm offers scientifically formulated supplements under the IM8 brand, sports nutrition products under the Europa platform, and direct-to-consumer DNA tests through the CircleDNA brand. It is also involved in establishing a Bitcoin treasury for the exploration of applications within the healthcare ecosystem. The company was founded by Sheng Wu Yeung and Chi Hung Tzang in 2014 and has dual headquartered in Charlotte, the United States and Hong Kong.

PRE At a Glance

Prenetics Global Ltd.
K11 Atelier Kings Road
Hong Kong,
Phone 852-2210-9588 Revenue 92.39M
Industry Financial Conglomerates Net Income -58,324,000.00
Sector Finance 2025 Sales Growth 201.721%
Fiscal Year-end 12 / 2026 Employees N/A
View SEC Filings

PRE Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.396
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.807
Enterprise Value to Sales 1.748
Total Debt to Enterprise Value 0.011

PRE Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 30.983
Total Asset Turnover 0.443

PRE Liquidity

Current Ratio 3.014
Quick Ratio 2.759
Cash Ratio 2.222

PRE Profitability

Gross Margin 52.975
Operating Margin -40.463
Pretax Margin -57.979
Net Margin -63.128
Return on Assets -25.268
Return on Equity -30.549
Return on Total Capital -29.878
Return on Invested Capital -30.247

PRE Capital Structure

Total Debt to Total Equity 1.012
Total Debt to Total Capital 1.002
Total Debt to Total Assets 0.868
Long-Term Debt to Equity 0.25
Long-Term Debt to Total Capital 0.248
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Prenetics Global Ltd - PRE

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
275.76M 21.74M 30.62M 92.39M
Sales Growth
- -92.12% +40.83% +201.72%
Cost of Goods Sold (COGS) incl D&A
144.21M 12.91M 20.21M 43.45M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
7.54M 7.79M 5.93M 3.78M
Depreciation
5.99M 5.88M 4.02M 2.70M
Amortization of Intangibles
1.56M 1.91M 1.91M 1.09M
COGS Growth
- -91.05% +56.48% +115.02%
Gross Income
131.55M 8.83M 10.42M 48.94M
Gross Income Growth
- -93.29% +17.95% +369.94%
Gross Profit Margin
+47.71% +40.61% +34.01% +52.98%
2022 2023 2024 2025 5-year trend
SG&A Expense
124.88M 61.34M 61.30M 86.33M
Research & Development
15.52M 11.66M 10.55M 5.13M
Other SG&A
109.36M 49.68M 50.76M 81.20M
SGA Growth
+3,067.05% -50.88% -0.06% +40.82%
Other Operating Expense
- - - -
-
Unusual Expense
185.65M 7.68M 8.82M 18.62M
EBIT after Unusual Expense
(178.98M) (60.20M) (59.71M) (56.00M)
Non Operating Income/Expense
(130.03K) 4.51M 3.99M 2.67M
Non-Operating Interest Income
- 472.19K 3.92M 2.04M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.20M 119.66K 203.00K 241.00K
Interest Expense Growth
- -97.15% +69.64% +18.72%
Gross Interest Expense
4.20M 119.66K 203.00K 241.00K
Interest Capitalized
- - - -
-
Pretax Income
(183.31M) (55.81M) (55.92M) (53.57M)
Pretax Income Growth
-5,442.27% +69.55% -0.20% +4.21%
Pretax Margin
-66.47% -256.68% -182.63% -57.98%
Income Tax
7.15M (269.36K) (7.87M) 40.00K
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- 7.43M 46.44K (7.41M)
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- (279.63K) (315.80K) (466.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(190.45M) (56.40M) (49.83M) (54.97M)
Minority Interest Expense
(54.000000000499995) (2.05M) (3.50M) (2.27M)
Net Income
(190.45M) (54.35M) (46.33M) (52.70M)
Net Income Growth
-5,658.36% +71.46% +14.76% -13.75%
Net Margin Growth
-69.06% -249.95% -151.29% -57.04%
Extraordinaries & Discontinued Operations
- (8.38M) 22.00K (5.63M)
Discontinued Operations
- (8.38M) 22.00K (5.63M)
Net Income After Extraordinaries
(190.45M) (62.72M) (46.30M) (58.32M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(190.45M) (62.72M) (46.30M) (58.32M)
EPS (Basic)
-37.5699 -5.5774 -3.7059 -4.1503
EPS (Basic) Growth
-4,190.27% +85.15% +33.56% -11.99%
Basic Shares Outstanding
5.07M 11.25M 12.49M 14.05M
EPS (Diluted)
-37.5699 -5.5774 -3.7059 -4.1503
EPS (Diluted) Growth
-4,190.27% +85.15% +33.56% -11.99%
Diluted Shares Outstanding
5.07M 11.25M 12.49M 14.05M
EBITDA
14.21M (44.72M) (44.96M) (33.60M)
EBITDA Growth
+460.46% -414.62% -0.54% +25.26%
EBITDA Margin
+5.15% -205.67% -146.83% -36.37%

Snapshot

Average Recommendation BUY Average Target Price 31.667
Number of Ratings 2 Current Quarters Estimate -0.808
FY Report Date 06 / 2026 Current Year's Estimate -3.148
Last Quarter’s Earnings -0.75 Median PE on CY Estimate N/A
Year Ago Earnings -3.79 Next Fiscal Year Estimate -0.238
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 4 4
Mean Estimate -0.81 -0.76 -3.15 -0.24
High Estimates -0.47 -0.39 -1.66 2.16
Low Estimate -1.24 -1.19 -4.89 -2.80
Coefficient of Variance -40.55 -45.80 -44.34 -872.41

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Prenetics Global Ltd in the News